DF
EW icon

Donoghue Forlines’s Edwards Lifesciences EW Stock Holding History

Donoghue Forlines’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,807
Closed -$742K – 254
2022
Q2 		$742K Buy
+7,807
New +$808K 0.19% 130
2018
Q2 		– Sell
-55,689
Closed -$2.59M – 162
2018
Q1 		$2.59M Buy
+55,689
New +$2.42M 0.22% 72

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Donoghue Forlines's EW Position: Q3 2022 in Review

Donoghue Forlines sold out of Edwards Lifesciences (EW) in Q3 2022, closing a stake of 7,807 shares — an estimated $742K sold.

Donoghue Forlines first reported a position in EW in Q1 2018 and held it in 2 quarters. The position peaked at $2.59M in Q1 2018. 1,246 funds tracked by Wall St. Rank hold EW as of Q3 2022.

  • Donoghue Forlines reported no remaining Edwards Lifesciences position as of Q3 2022 after selling out during the quarter.
  • Donoghue Forlines sold 7,807 Edwards Lifesciences shares in Q3 2022, an estimated $742K.
  • Donoghue Forlines first reported a position in Edwards Lifesciences in Q1 2018 and held it in 2 quarters.
  • Donoghue Forlines's Edwards Lifesciences position peaked at $2.59M in Q1 2018.
  • 1,246 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2022.

Based on Donoghue Forlines's 13F filing for Q3 2022, filed 7 Nov 2022.